On March 3, 2026, the U.S. Food and Drug Administration granted Vanda Pharmaceuticals a formal evidentiary public hearing to review the agency’s proposal to refuse approval of the company’s supplemental new drug application for HETLIOZ® in the treatment of jet‑lag disorder. The hearing, conducted under 21 CFR Part 12, will allow Vanda to present evidence and arguments before a presiding officer who will issue an initial decision under §12.120.
The decision follows a court ruling in August 2025 by the U.S. Court of Appeals for the D.C. Circuit that set aside an earlier FDA refusal and directed the agency to resolve the application or hold a hearing. The FDA’s letter confirming the hearing, dated March 2, 2026, marked the first formal drug‑approval hearing in more than four decades, underscoring the rarity of the event and the regulatory significance of the case.
Vanda’s HETLIOZ® is currently approved for Non‑24‑Hour Sleep‑Wake Disorder and nighttime sleep disturbances associated with Smith‑Magenis syndrome, and it holds orphan‑drug exclusivity for the former indication. A successful approval for jet‑lag would expand the drug’s market beyond its existing exclusivity, potentially adding a new therapeutic indication to a product that already generates stable cash flow. The company’s other commercial products include Fanapt® for schizophrenia, with net product sales of $117.3 million in 2025, and NEREUS™ (tradipitant) for motion sickness, which received FDA approval in January 2026.
Financially, Vanda reported full‑year 2025 total revenues of $216.1 million, up 9% from $198.8 million in 2024, while the net loss widened to $220.5 million from $18.9 million in 2024, largely due to a $113.7 million non‑cash income‑tax charge. The hearing could therefore provide a critical revenue boost and strengthen the company’s financial position, offsetting the significant loss incurred in the prior year.
CEO Mihael H. Polymeropoulos said, “We are encouraged by the FDA’s decision to grant a formal evidentiary hearing on the proposed refusal of our jet‑lag application for HETLIOZ®. This procedural victory reflects Vanda’s 7‑year persistence in advocating for fairness and the rigorous pursuit of scientific truth on behalf of patients. At the same time, it represents a significant reform step by the FDA toward greater transparency—the first such formal drug approval hearing in over 40 years.” The hearing is seen as a pivotal moment that could reshape Vanda’s product portfolio and market outlook.
No immediate market reaction data were available at the time of publication, but the hearing’s outcome will be closely watched by investors and analysts as it could alter the company’s revenue trajectory and competitive positioning in the sleep‑disorder therapeutics space.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.